Table 2.
Levels of TGF-β1 (mean ± s.d.) in supernatants of adherent cells from peripheral blood mononuclear cells (PBMC) from patients with different clinical forms of leprosy (LL/BL with ENL, LL/BL without ENL, BB/BT without RR, BB/BT with RR, TT) and healthy individuals (HI) measured by ELISA
| Clinical forms and healthy individuals | Type of stimulus | Concentration of TGF-β1 (pg/ml), 48 h, mean ± s.d. |
|---|---|---|
| LL/BL with ENL | RPMI | 6034·92 ± 3807·58* |
| (n = 5) | LPS | 6334·80 ± 3578·11* |
| PGL-1 | 6325·97 ± 3894·93* | |
| LL/BL without ENL | RPMI | 960·23 ± 411·86 |
| (n = 5) | LPS | 907·71 ± 344·30 |
| PGL-1 | 1065·86 ± 474·54 | |
| BB/BT without RR | RPMI | 1394·93 ± 171·00 |
| (n = 3) | LPS | 1740·80 ± 328·60 |
| PGL-1 | 1770·60 ± 287·80 | |
| BB/BT with RR | RPMI | 982·60 ± 139·20 |
| (n = 3) | LPS | 795·60 ± 331·50 |
| PGL-1 | 1516·98 ± 527·90 | |
| TT | RPMI | 204·98 ± 194·22** |
| (n = 3) | LPS | 208·43 ± 211·32** |
| PGL-1 | 105·42 ± 138·71**† | |
| HI | RPMI | 565·11 ± 315·23 |
| (n = 9) | LPS | 657·05 ± 358·04 |
| PGL-1 | 638·76 ± 285·01 |
*
Statistically significant compared with other clinical forms of leprosy or healthy individuals (LL/BL with ENL versus LL/BL without ENL, P < 0·01; LL/BL with ENL versus BB/BT with RR, P < 0·01; LL/BL with ENL versus TT, P < 0·001; LL/BL with ENL versus HI, P < 0·001).
**
Statistically significant compared with other clinical forms of leprosy (P < 0·001).
†
Statistically significant compared with healthy individuals under PGL-1 stimulation only (P < 0·05).